Logo
Innovation for Women’s Health

We fight endometriosis with AI, advanced surgery, and microbiome science

An integrated approach to diagnosis, treatment, and prevention—serving the health and future of 190 million women worldwide.

Partner with us Investor information GDPR-ready platforms

The Challenge: Endometriosis

A chronic disease causing severe pain and infertility, affecting quality of life for millions.

190M
Women & girls affected worldwide
7–10y
Average diagnostic delay
€€€
Billions in annual economic losses

Gut microbiome imbalance is a key driver of inflammation and hormone dysregulation.

What We Build

1) AI-Powered Early Diagnosis

Multi-modal models over clinical data, imaging, and biomarkers to shorten the time-to-diagnosis; privacy by design with GDPR compliance.

2) Nerve-Sparing Surgery

Advanced laparoscopic and robot-assisted techniques to preserve nerves and fertility and reduce post-op complications.

3) Research, Education & Outreach

Scientific programs, international surgical training, congresses and online courses to raise global standards of care.

4) Microbiome Restoration

Supplements, diagnostics and personalized, non-surgical solutions to rebalance gut health and slow disease progression.

Leadership & Expertise

Dr. Marcello Ceccaroni — international authority in severe endometriosis care; creator of the multi-award-winning Negrar Method – Nerve Sparing, Golden Laparoscope Award recipient, with publications in The Lancet and other leading journals.

Backed by a team across biomedicine, AI, surgery and research; supported by international advisors and partners.

For Investors

We are open to equity crowdfunding and strategic investors. As an innovative startup in Italy, qualifying investors may access fiscal benefits (up to 50% deduction within limits and holding periods).

Traceability and reporting available for eligibility verification.

Why now?

  • Integrated edge: AI × Surgery × Microbiome
  • Large unmet need, growing market
  • Clear 2025–2027 roadmap

Contact

Interested in pilots, research partnerships, or investing? Let’s talk.

We’ll get back to you shortly.